A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
← catalyst calendarNCT06830629 · readout ≤ 41 d
Sponsored by Maze Therapeutics (industry) · MAZE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
74estimated
Sites
79
Countries
France, United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-02-05 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Proteinuric Kidney Disease
Intervention
- Drug: MZE829
Primary outcome
what the primary-completion date above is the date OFSafety and tolerability as assessed by incidence of adverse events (AEs)
measured Baseline to Week 12
Permalink · MAZE's whole pipeline · Catalyst calendar · Every registered study · What changed